insulin icodec (once weekly)
Jump to navigation
Jump to search
Introduction
Not yet FDA-approved (Oct 2020)
Indications
* glycemic control with once weekly icodec non-inferior to daily glargine[3]
* with provided application, lowers hemoglobin A1c at 52 weeks more than insulin degludec or insulin glargine[5]
Dosage
- start 70 units of insulin icodec SC weekly
- titrate dose weekly, with a fasting blood glucose goal of 70-108 mg/dL
Adverse effects
- hypoglycemia (slightly higher incidence than with glargine)[3]
More general terms
References
- ↑ Rosenstock J et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020 Sep 22; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32960514 https://www.nejm.org/doi/10.1056/NEJMoa2022474
- ↑ Bajaj HS, Bergenstal RM, Christoffersen A et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: A phase 2 randomized controlled trial. Diabetes Care 2021 Jul; 44:1586. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33875485 https://care.diabetesjournals.org/content/44/7/1586
Lingvay I, Buse JB, Franek E et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care 2021 Jul; 44:1595. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33875484 https://care.diabetesjournals.org/content/44/7/1595 - ↑ 3.0 3.1 3.2 Mathieu C et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): A phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet 2023 May 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37156252 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00520-2/fulltext
- ↑ Rosenstock J, Bain SC, Gowda A et al Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. 2023. June 24 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37356066 https://www.nejm.org/doi/full/10.1056/NEJMoa2303208
Lingvay I, Asong M, Desouza C et al Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes. The ONWARDS 3 Randomized Clinical Trial. N Engl J Med. 2023. June 24 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37354562 https://jamanetwork.com/journals/jama/fullarticle/2806635 - ↑ 5.0 5.1 Bajaj HS, Aberle J, Davies M, et al. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5): A Randomized Trial. Ann Intern Med. 2023 Sep 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37748181 https://www.acpjournals.org/doi/10.7326/M23-1288